(Technetii (99mTc) succimeri multiplex injectio) (September 2017)
[Pages:7]Working document QAS/17.735 September 2017
Draft document for comment
1 2
3 Monograph for Technetium (99mTc) succimer complex injection
4
(Technetii (99mTc) succimeri multiplex injectio)
5
(September 2017)
6
7 8 9
DRAFT FOR COMMENT
Please send any comments on the revision of this draft document to Dr Sabine Kopp Group Lead, Medicines Quality Assurance, Technologies Standards and Norms (kopps@who.int) with a copy to Ms Xenia Finnerty (finnertyk@who.int ) by 1 November 2017.
Our working documents will be sent out electronically only and will also be placed on the Medicines website for comment under "Current projects". If you do not already receive our draft working documents please let us have your email address (to bonnyw@who.int) and we will add it to our electronic mailing list.
10 11 12 13 ? World Health Organization 2017
14 All rights reserved.
15 This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft 16 may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any 17 form or by any means outside these individuals and organizations (including the organizations' concerned staff and member 18 organizations) without the permission of the World Health Organization. The draft should not be displayed on any website.
19 Please send any request for permission to:
20 Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies Standards and Norms, Department of Essential 21 Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland. Fax: (41-22) 791 4730; email: 22 kopps@who.int.
23 The designations employed and the presentation of the material in this draft do not imply the expression of any opinion 24 whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its 25 authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines 26 for which there may not yet be full agreement.
27 The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended 28 by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions 29 excepted, the names of proprietary products are distinguished by initial capital letters.
30 All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. 31 However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility 32 for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for 33 damages arising from its use.
34 This draft does not necessarily represent the decisions or the stated policy of the World Health Organization. 35
Working document QAS/17.735 page 2
36
SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/17.735
37
Monograph for Technetium (99mTc) succimer complex injection
38
(Technetii (99mTc) succimeri multiplex injectio)
39
IAEA consultation
Date 3?7 December 2012
IAEA consultation
6?10 May 2013
Draft monograph received from IAEA in track-change mode according to format/template described in QAS/13.544
June 2013
Discussion at informal consultation on new medicines, quality control and laboratory
12?14 June 2013
standards
Feedback to IAEA by WHO Secretariat
June 2013
Circulation for comments to IAEA and WHO Panel of Experts
Feedback to IAEA, as appropriate
June 2013 August?September 2013
Discussion during WHO Expert Committee
on Specifications for Pharmaceutical
October 2013
Preparations
Follow up by IAEA, including review of comments received
October 2013?February 2014
Discussion of revised version at IAEA consultation, Vienna, Austria
February 2014
Finalization by IAEA
February 2014
Circulation of revision to WHO and IAEA mailing list of experts for comments
Compilation of feedback
March 2014 April 2014
Discussion at informal consultation on Specifications for The International Pharmacopoeia and laboratory standards in Geneva
3?4 April 2014
40
Compilation of feedback to IAEA
Presentation to forty-ninth WHO Expert Committee on Specifications for Pharmaceutical Preparations
Update during the fiftieth WHO Expert Committee on Specifications for Pharmaceutical Preparations Review and discussion of situation regarding monograph development for radiopharmaceuticals at informal consultation on quality control laboratory tools and specifications for medicines
IAEA update during the fifty-first WHO Expert Committee on Specifications for Pharmaceutical Preparations
Review and discussion during informal consultation on quality control laboratory tools and specifications for medicines
IAEA delegated final review and modifications to Professor Alain Nicolas, France
Mailing of revised monograph for public consultation
Presentation to the fifty-second WHO Expert Committee on Specifications for Pharmaceutical Preparations
Any further action as necessary
Working document QAS/17.735 page 3
May 2014 13?17 October 2014 12?16 October 2015 9?11 May 2016
17?21 October 2016 2?4 May 2017 May?September 2017 September 2017 16?20 October 2017
41 42 43 44 45
Working document QAS/17.735 page 4
46
Monograph for Technetium (99mTc) succimer complex injection
47
(Technetii (99mTc) succimeri multiplex injectio)
48 49 Latin.Technetii (99mTc) succimeri multiplex injectio.
50 51 English. Technetium (99mTc) succimer complex injection.
52 53 Chemical name. (2R,3S)-2,3-disulfanylbutanedioic acid complexed with [99mTc] technetium 54 (III).
55 56 Other names. (99mTc)-meso-2,3-dimercaptosuccinic acid complex injection; (99mTc)-DMSA 57 injection, 99mTc-Succimer, Technetium-99m-DMSA, Technetium- [99mTc] succimer, 99mTc(III)58 DMSA
59 60 Description. Technetium (99mTc) succimer complex injection is a clear, colourless aqueous 61 solution. 62 63 Technetium-99m has a half-life of 6.02 hours.
64 65 Category. Diagnostic.
66 67 Storage. Technetium (99mTc) succimer complex injection is kept in single-dose containers, at a 68 temperature between 15 ?C and 30 ?C and should be protected from light.
69 70 Labelling. The label complies with the General monograph Radiopharmaceuticals. (Note: A 71 beyond-use time of 30 minutes shall be stated on the label upon constitution with Sodium 72 Pertechnetate (99mTc) injection).
73 74 Manufacture 75 76 Technetium (99mTc) succimer complex injection is prepared aseptically from sterile starting
77 materials such as a sterile kit containing meso-2,3-dimercaptosuccinic acid (DMSA) and a 78 stannous salt with Sodium pertechnetate (99mTc) injection (Fission) or Sodium Pertechnetate 79 (99mTc) injection (Non-fission). It may have the pH adjusted and may contain chelating, 80 stabilizing, filling, antioxidants such as ascorbic acid, and inert additives as well as antimicrobial 81 preservatives and buffers. (99mTc) DMSA is prepared in acidic pH and the oxidation state of 82 99mTc is 3+ in this complex, otherwise its biological behavior will be different. The injection may 83 also be prepared under aseptic processing combined with sterilization by filtration (see 5.8 84 Methods of sterilization). The Technetium (99mTc) DMSA injection should be used within 4 85 hours from the stated date and time of preparation. 86
87 Additional information 88 89 Wherever V is used within the tests of this monograph, V is the maximum recommended dose, in 90 millilitres.
Working document QAS/17.735 page 5
91 Requirements
92
93 Complies with the monograph for Parenteral Preparations and with that for
94 Radiopharmaceuticals.
95
96 Definition
97 98 Technetium (99mTc) succimer complex injection, is a sterile solution of Sodium pertechnetate 99 (99mTc) injection (Fission) or Sodium Pertechnetate (99mTc) injection (Non-fission) complexed
100 with meso-2,3-dimercaptosuccinic acid (DMSA) that is present in excess. The injection is
101 suitable for intravenous administration and contains sufficient sodium chloride to make the
102 solution isotonic. The content of technetium-99m is not less than 90% and not more than 110%
103 of the content of technetium-99m stated on the label at the reference date and time.
104 105 Not less than 95.0% of the total technetium-99m radioactivity is present as technetium (99mTc)
106 succimer complex. The injection contains a variable quantity of tin (Sn) not greater than 1
107 mg/mL.
108
109 Identity tests
110
111 ? Either tests A and C or tests B and C may be applied.
112
113 A. Record the gamma-ray spectrum using a suitable instrument with a sample of technetium-
114
99m, suitably diluted if needed. The spectrum is concordant with the reference spectrum of
115
a specimen of technetium-99m in that it exhibits a major peak of 141 keV.
116
117
Standardized technetium-99m solutions are available from laboratories recognized by the
118
relevant national or regional authority.
119
120 B. The half-life determined using a suitable detector system is between 5.72 and 6.32 hours.
121
122 C. In the test for Radiochemical purity, the chromatogram obtained contributes to the
123
identification of the Technetium (99mTc) DMSA.
124
125 pH. Carry out the test as described under 1.13 or R1.5 Determination of pH under the
126 monograph for Radiopharmaceuticals, the pH of the injection should be between 2.3 and 3.5.
127
128 Tin. Carry out the test as described under R2.1.4 Tin estimation by UV absorption, using 1.0 mL
129 of a test solution prepared by diluting 1.5 mL of the injection to be examined to 25.0 mL with
130 hydrochloric acid (103 g/L) VS and mixing thoroughly. Prepare the reference solution by
131 dissolving 0.115 g of stannous chloride R using a solution in hydrochloric acid R (103 g/L HCl)
132 and dilute to 1000.0 mL using the same acid. To the test solution and to 1.0 mL of the reference
133 solution add 0.05 mL of thioglycollic acid R, 0.1 mL of dithiol reagent R, 0.4 mL of a 20 g/L
134 solution of sodium laurilsulfate R, 3.0 mL of 21 g/L solution of hydrochloric acid R. Mix and
135 measure the absorbance of each solution at 540 nm using 21 g/L solution of hydrochloric acid as
Working document QAS/17.735 page 6
136 a compensation liquid. The absorbance of the test solution is not greater than that of the 137 reference solution; not more than 1 mg of Sn per mL. 138 139 Biodistribution 140 141 Perform the test as described under R3.1 Biological distribution using three rats each weighing 142 150?250 g. Inject each of the three rats with a volume not greater than 0.2 mL and containing not 143 more than 0.1 mg of dimercaptosuccinic acid intravenously in a caudal vein or a saphenous vein. 144 Euthanize the rats 1 hour after the injection. Remove the kidneys, the liver, the spleen, the 145 stomach, the lungs and, if a caudal vein has been used for the injection, the tail. Using a suitable 146 instrument determine the radioactivity in these organs. 147 148 In not fewer than two of the three rats used, the radioactivity in the kidneys is not less than 40%, 149 and that in the liver is not more than 10.0%, that in the lungs is not more than 5.0% and that in 150 the stomach is not more than 2.0%. 151 152 Sterility. Test for sterility will be initiated on the day of manufacture. The injection may be 153 released for use before completion of the test. 154 155 The injection complies with 3.2 Test for sterility, modified as described in the monograph for 156 Radiopharmaceuticals. 157 158 Bacterial endotoxins. The test must be completed prior the preparation release. 159 160 Perform the test as described under 3.4 Test for bacterial endotoxins, modified as described in 161 the monograph for Radiopharmaceuticals. The injection contains not more than 175/V I.U. of 162 endotoxins per millilitre. 163 164 Radiochemical purity 165 166 Either test 1 or test 2 to be applied 167 168 Test 1. Perform the test as described under 1.14.2 Paper chromatography and ascending 169 conditions using paper for chromatography R. Two strips of Whatman No 1 (size 1 x 8 cm) are 170 used. The solvent to be used is acetone. Spot about 2?5 ?L of 99mTc(III)-DMSA injection at 1 cm 171 from one end of the strip in duplicate. 172 173 Develop the chromatogram until the solvent front reaches 6 cm from the point of spotting. Cut 174 the strip into 2 sections; the lower half (0?3 cm) and the upper half (3?6 cm) and count in a well175 type scintillation counter. Free pertechnetate impurity (impurity A) has a Rf of 0.9?1.0 in the 176 upper half. 177 178 The percentage of activity in the 99mTc-pertechnetate zone should not be more than 2.0% of the 179 total activity. The radiochemical purity of 99mTc(III)-DMSA (Rf = 0.0 - 0.1) should not be less 180 than 95.0%. 181
Working document QAS/17.735 page 7
182 Test 2. Perform the test as described under 1.14.1 Thin-layer chromatography, using silica gel
183 for chromatography R as the coating substance. Heat the plate at 110 ?C for 10 minutes. Apply to
184 the plate about 5 L of the injection to be examined, suitably diluted to give an optimum count
185 rate. Develop immediately for a distance of about 10 cm with methyl ethyl ketone R. Allow the
186 plate to dry in air and determine the radioactivity distribution by a suitable method. In this 187 system, the technetium 99mTc(III)-DMSA complex has a Rf value of 0.0?0.1 and the 188 (99mTc)pertechnetate ion has a Rf value of 0.9?1.0. Not less than 95.0% of the total technetium189 99m radioactivity is present as 99mTc(III)-DMSA. Not more than 2.0% of the total technetium190 99m radioactivity is present as (99mTc)pertechnetate ion (impurity A).
191
192 Radioactivity
193
194 Measure the radioactivity using a suitable counting instrument as described under R.1.1
195 Detection and measurement of radioactivity.
196
197 Impurities
198 199 A.
[99mTc] pertechnetate ion.
200
201
***
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- 6 8 5 7 6 1 1 2 0 0 66 2 1 8 1 7 67 7 6
- notice to attorneys notice of new revised or repealed forms for the
- new york city department of correction monthly city of new york
- units conversion tables
- high pressure stainless steel parker hannifin
- song chuan 735 mouser electronics
- technetii 99mtc succimeri multiplex injectio september 2017
- fespa berlin 2022 event date may 31 2022 jun 03 2022 pdf created
- labor force estimates release
- suspend the rules and pass the bill h r 7667 with an amendment new
Related searches
- september themes for toddlers
- today in history september 27 msn
- september party themes for adults
- sure dividend september 2019
- september theme ideas
- day in history september 27
- september curriculum for toddlers
- september themes for preschool
- september equinox
- today in history september 6
- september health observances 2019
- september preschool lesson plans themes